Skip to content

Pain Disengagement Training (Open Pilot)

Pain Disengagement Training: A Self-directed Intervention for Pain Catastrophizing (Open Pilot)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06870162
Enrollment
10
Registered
2025-03-11
Start date
2025-10-14
Completion date
2026-12-10
Last updated
2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Musculoskeletal Pain

Keywords

pain catastrophizing

Brief summary

The investigators aim to conduct an open pilot trial to determine the initial feasibility of a self-directed writing-based intervention in individuals with chronic musculoskeletal pain and elevated pain catastrophizing. The investigators will assess the feasibility of recruitment, acceptability of the treatment, credibility and participant satisfaction, treatment adherence, and feasibility of assessments following pre-specified benchmarks.

Detailed description

Mind-body interventions are some of the most effective treatments for chronic pain, yet due to lack of resources, many are inaccessible to the patients who need them. The investigators seek to fill this gap by developing and testing Pain Disengagement Training (PDT) for the treatment of chronic pain catastrophizing, a key risk factor for pain interference. The investigators will administer the PDT treatment in a small number (approximately 10) of participants to evaluate initial benchmarks (the feasibility of recruitment, acceptability of the treatment, credibility and participant satisfaction, treatment adherence, and feasibility of assessments) and to assess participants' experience with the intervention using qualitative exit interviews. Results will inform the refinement of the intervention for a future larger trial.

Interventions

BEHAVIORALPain Disengagement Training

The intervention involves approximately 8 sessions. The first session will involve a psychoeducation component describing the association between negative emotions and pain and the rationale for the intervention strategies. The intervention sessions will consist of approximately 30 minutes of writing alternating between imaginal exposure writing and positive writing periods alternating back and forth (e.g., 3-5 minutes of imaginal exposure writing followed by 3-5 minutes of positive writing before returning to imaginal exposure writing, etc.). Exposure writing will involve writing about a pain-related catastrophic worry repeatedly until it becomes less anxiety-provoking. The positive writing topics will change with each prompt and will be structured by session theme (e.g., values/goals, meaningful activities). They will also complete between session practice by setting aside a time for worrying and then completing a meaningful activity.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER
National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Outpatient adults (i.e., greater than or equal to 18) 2. Has self reported chronic musculoskeletal pain (i.e., pain persisting for at least 3 months) 3. Pain score greater than or equal to 4 (moderate) on the Numerical Rating Scale 4. Pain catastrophizing score greater than or equal to 20 on Pain Catastrophizing Scale 5. Willingness to engage in a writing-based intervention and self-reported ability to write or type for at least 30 minutes in a sitting 6. Received care at Massachusetts General Hospital 7. English verbal and writing fluency

Exclusion criteria

1. Clinically significant change in therapy or medication in the past 3 months 2. Severe untreated mental health condition (e.g., psychosis) 3. Active suicidality with history of plan or current intent 4. Serious illness expected to worsen in the next 6 months (e.g., cancer) 5. Untreated substance use problem that, per patient's self-report, would interfere with the ability to complete the intervention.

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of recruitmentBaseline, post-test (6 weeks)\>70% participants approached agree to participate in the intervention
Acceptability of treatmentBaseline, post-test (6 weeks)\>70% of participants attend at least 6 out of 8 sessions
Credibility and Expectancy QuestionnaireBaselineMeasures perception that the treatment is credible and will offer improvements. Credibility (4 items) is rated from 1-9 with higher scores indicating more credibility. Expectancy is rated from 0-10 with higher scores indicating greater expectancy of improvement.
Client Satisfaction QuestionnairePost-test (6 weeks)Measure of client satisfaction with a program or intervention. 8-item scale measured from 1 to 4 with greater scores indicating greater satisfaction.
Adherence to interventionMid-interventionPercent of writing sections demonstrate correct themes (e.g., anxiety words in imaginal exposure writing)
Feasibility of assessmentsBaseline, post-test (6 weeks)\>70% of participants have no measures fully missing

Secondary

MeasureTime frameDescription
Numerical Rating ScaleBaseline, post-test (6 weeks)Rating of pain intensity on a 0-10 1-item scale with greater scores indicating greater pain intensity
Graded Chronic Pain ScaleBaseline, post-test (6 weeks)Measure of pain severity. 3-item scale rated from 0 to 10 with greater scores indicating greater pain severity and interference
PROMIS Pain Interference scaleBaseline, post-test (6 weeks)Assesses pain interference in the past 7 days in activities, work, chores, etc. 8-item scale (1 - not at all to 5 - very much) with greater scores indicating greater pain interference.
Brief Pain InventoryBaseline, post-test (6 weeks)Assesses pain intensity (4 items) on a 0 to 10 scale with greater scores indicating worse pain intensity and interference.
Patient Health Questionnaire - 9Baseline, post-test (6 weeks)Measure of depressive symptoms. 9-item scale rated from 0 to 3 with greater scores indicating greater depressive symptoms.
PROMIS depression scale-8Baseline, post-test (6 weeks)Measure of depressive symptoms. 8-item scale rated from 1 to 5 with greater scores indicating greater depressive symptoms.
Penn State Worry Questionnaire - abbreviatedBaseline, post-test (6 weeks)8-item measure of worry rated from 1 to 5 with greater scores indicating greater worry.
Pain Catastrophizing ScaleBaseline, post-test (6 weeks)Assesses magnification, helplessness, and rumination in response to pain. 13-item scale rated 0 to 4 with greater scores indicating greater pain catastrophizing.
Pain Anxiety Symptom Scale - Short Form (PASS-20)Baseline, post-test (6 weeks)Assesses fear and anxiety in response to pain. 20-item scale rated 0 to 5 with greater scores indicating greater pain anxiety.
Worry Disengagement QuestionnaireBaseline, post-test (6 weeks)Measures ability to shift attention from worry. 4-item scale rated from 0 to 10 with greater scores indicating greater ability to shift attention away from worry.
Behavioral Activation for Depression Scale - Short FormBaseline, post-test (6 weeks)Assesses engagement in meaningful activities. 9-item measure rated from 0 to 6 with greater scores indicating greater activity engagement.
Positive emotion rating scaleMid-interventionAssesses level of emotional intensity on a 4-item scale from 1 to 5 with greater scores indicating more positive emotionality.
Contrast Avoidance Questionnaire-General Emotion and Worry subscalesBaseline, post-test (6 weeks)Measures ability to sustain negative emotionality to protect against sudden shifts in emotion. 25-item scale rated from 1 to 5 with greater scores indicating greater avoidance of contrasting emotional states.
PROMIS meaning and purpose scale short form 4aBaseline, post-test (6-weeks)4 item scale assessing meaning and fulfillment in life (1 to 5 rating scale)
Self-Compassion ScaleBaseline, Post-test (6 weeks)12 item 1 to 5 scale measuring self-compassion

Countries

United States

Contacts

CONTACTKatherine McDermott, PhD
kmcdermott@mgh.harvard.edu(617) 643-4208
CONTACTAna-Maria Vranceanu, PhD
avranceanu@mgh.harvard.edu
PRINCIPAL_INVESTIGATORKatherine McDermott, PhD

Massachusetts General Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026